首页 > 市场调查报告书 > 製药

糖尿病

市场调查报告书

商品编码

1448720

全球增殖性糖尿病视网膜病变市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Proliferative Diabetic Retinopathy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年02月01日 | 出版商:

Value Market Research | 英文 294 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计到 2032 年，全球增殖性糖尿病视网膜病变市场的市场规模将从 2023 年的 63.3 亿美元达到近 156.9 亿美元，2024-2032 年研究期间的CAGR为 10.62%。

增殖性糖尿病视网膜病变 (PDR) 是糖尿病视网膜病变的晚期和严重阶段，糖尿病患者可能会出现这种眼睛疾病。糖尿病视网膜病变是一种与糖尿病相关的併发症，会影响视网膜血管（眼睛后部的感光组织）。 PDR 的特征是视网膜中异常血管的生长（新生血管）。

市场动态

增殖性糖尿病视网膜病变 (PDR) 市场由多种因素驱动，主要受到全球糖尿病（尤其是第 2 型糖尿病）盛行率不断上升的影响。人口老化的加剧进一步增加了长期糖尿病的风险，导致糖尿病性视网膜病变进展至增殖期的发生率更高。医疗保健专业人员和患者意识的提高，加上视网膜成像技术的进步，有助于早期发现和有针对性的治疗。治疗方法的持续创新，包括药物干预，有助于不断发展的 PDR 管理格局。医疗保健服务取得的改善、政府倡议以及医疗保健组织和研究机构之间的合作进一步增强了对 PDR 的整体回应。病患教育和赋权在促进定期眼科筛检和糖尿病管理方面发挥关键作用，这对于早期介入至关重要。全球认识到糖尿病视网膜病变是一个重大的健康问题，加上经济发展和医疗基础设施的改善，共同製定了一项全面的策略来应对与增殖性糖尿病视网膜病变相关的挑战，旨在减少视力损伤并提高患者的治疗效果。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球增殖性糖尿病视网膜病变市场的各个细分市场进行了包容性评估。增殖性糖尿病视网膜病变产业的成长和趋势为本研究提供了整体方法。

市场区隔

增殖性糖尿病视网膜病变市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人口统计数据以及即将到来的机会。

按药物类别

抗VEGF药物
皮质类固醇

按管理方式

可注射
口服
其他的

按配销通路

医院药房
零售药局
网路药局

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的增殖性糖尿病视网膜病变市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。增殖性糖尿病视网膜病变市场的主要参与者包括基因泰克公司、诺华公司、再生元製药公司、辉瑞公司、默克公司、西普拉公司、艾伯维公司、博士健康公司、参天製药公司、有限公司、Alimera Sciences、Intas Pharmaceuticals Ltd。本部分包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布，以及其他进展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：增殖型糖尿病视网膜病变公司的竞争格局

增殖性糖尿病视网膜病变市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

公司股份分析
市场集中度
Genentech Inc.

公司简介
公司收入
产品
最近的发展

Novartis AG

公司简介
公司收入
产品
最近的发展

Regeneron Pharmaceuticals Inc.

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

Merck KGaA

公司简介
公司收入
产品
最近的发展

Cipla Inc.

公司简介
公司收入
产品
最近的发展

AbbVie Inc.

公司简介
公司收入
产品
最近的发展

Bausch Health Companies Inc.

公司简介
公司收入
产品
最近的发展

Santen Pharmaceutical Co. Ltd.

公司简介
公司收入
产品
最近的发展

Alimera Sciences

公司简介
公司收入
产品
最近的发展

Intas Pharmaceuticals Ltd.

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR112113620

The global demand for Proliferative Diabetic Retinopathy Market is presumed to reach the market size of nearly USD 15.69 Billion by 2032 from USD 6.33 Billion in 2023 with a CAGR of 10.62% under the study period 2024 - 2032.

Proliferative diabetic retinopathy (PDR) is an advanced and serious stage of diabetic retinopathy, an eye condition that can occur in individuals with diabetes. Diabetic retinopathy is a diabetes-related complication that affects the retinal blood vessels, the light-sensitive tissue at the back of the eye. PDR is characterized by the growth of abnormal blood vessels (neovascularization) in the retina.

MARKET DYNAMICS

The Proliferative diabetic retinopathy (PDR) market is driven by several factors, primarily influenced by the increasing global prevalence of diabetes, particularly type 2 diabetes. A growing aging population further raises the risk of prolonged diabetes, leading to a higher incidence of diabetic retinopathy progressing to the proliferative stage. Increased awareness among healthcare professionals and patients, coupled with technological advancements in retinal imaging, facilitates early detection and targeted treatment. Ongoing innovations in treatment approaches, including pharmacological interventions, contribute to the evolving landscape of PDR management. Improved access to healthcare services, government initiatives, and collaborations among healthcare organizations and research institutions further enhance the overall response to PDR. Patient education and empowerment play pivotal roles in promoting regular eye screenings and diabetes management, which is crucial for early intervention. The global recognition of diabetic retinopathy as a significant health concern, coupled with economic development and healthcare infrastructure improvements, collectively shapes a comprehensive strategy to address the challenges associated with proliferative diabetic retinopathy, aiming to reduce vision impairment and enhance patient outcomes.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of proliferative diabetic retinopathy. The growth and trends of proliferative diabetic retinopathy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the proliferative diabetic retinopathy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Anti-VEGF Agents
Corticosteroids

By Mode Of Administration

Injectable
Oral
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Proliferative Diabetic Retinopathy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Proliferative Diabetic Retinopathy market include Genentech, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Merck KGaA, Cipla Inc., AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Alimera Sciences, Intas Pharmaceuticals Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PROLIFERATIVE DIABETIC RETINOPATHY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Mode of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Anti-VEGF Agents Historic and Forecast Sales by Regions
5.5 Corticosteroids Historic and Forecast Sales by Regions

6 . GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET ANALYSIS BY MODE OF ADMINISTRATION

6.1 Overview by Mode of Administration
6.2 Historical and Forecast Data
6.3 Analysis by Mode of Administration
6.4 Injectable Historic and Forecast Sales by Regions
6.5 Oral Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1 Overview by Distribution Channel
7.2 Historical and Forecast Data
7.3 Analysis by Distribution Channel
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE PROLIFERATIVE DIABETIC RETINOPATHY COMPANIES

9.1. Proliferative Diabetic Retinopathy Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF PROLIFERATIVE DIABETIC RETINOPATHY INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Genentech Inc.
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Novartis AG
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Regeneron Pharmaceuticals Inc.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Pfizer Inc.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Merck KGaA
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Cipla Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. AbbVie Inc.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Bausch Health Companies Inc.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Santen Pharmaceutical Co. Ltd.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Alimera Sciences
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Intas Pharmaceuticals Ltd.
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments